Diabetes Drug Cuts Addiction Deaths by 50% in Major Study

A guest at a dinner party recently stared at her wine glass with complete indifference, something that would have been unthinkable months earlier. She wasn't trying to quit drinking—the craving had simply vanished after starting Ozempic for weight loss.

Stories like hers are now flooding clinics and social media feeds across the country. Patients taking GLP-1 drugs for diabetes or obesity report losing interest in cigarettes, alcohol, even gambling.

The science is catching up fast. A new study published in the BMJ tracked more than 600,000 people and found stunning results: 50% fewer substance-related deaths, 39% fewer drug overdoses, and 26% fewer drug-related hospitalizations among those taking GLP-1 medications.

The drugs reduced the risk of new substance use disorders across alcohol, opioids, cocaine, cannabis, and nicotine. A Swedish study found them more effective at preventing alcohol-related hospitalizations than medications specifically designed to treat alcohol addiction.

Researchers tested the drug semaglutide on vervet monkeys, primates that naturally drink alcohol like humans do. The monkeys drank significantly less, not because alcohol made them sick, but because they simply lost interest.

Why This Inspires

What makes this discovery remarkable is that these medications work across all addictive substances. A drug created for blood sugar appears to quiet cravings for substances with completely different effects on the body.

The pattern suggests something profound: these addictions may share a common biological driver we couldn't see until now. Researchers call it "drug noise," the relentless, unbidden craving that pulls people back despite every intention to stop.

GLP-1 isn't just a gut hormone. It's also produced in the brain, where its receptors cluster in regions controlling reward, motivation, and impulse control—the exact circuits hijacked by addiction.

The timing couldn't be more critical. The U.S. saw 80,000 overdose deaths in 2024, plus 178,000 deaths yearly from excessive alcohol use. For cocaine and methamphetamine addiction, no approved medication exists at all.

Current medications for alcohol and opioid disorders are decades old and modestly effective. Fewer than 2% of people with alcohol use disorder receive any of them—a treatment rate we'd never accept for any other deadly disease.

GLP-1 drugs are the first class showing promise against multiple addictive substances simultaneously. Important questions remain about long-term effectiveness and whether cravings return after stopping the medication, but early evidence suggests millions already taking these drugs for obesity may be benefiting in unexpected ways.

Clinical trials are needed to measure what truly matters: overdoses prevented, hospitalizations avoided, and lives saved. For now, researchers are watching closely as a diabetes medication reveals something we've long suspected—that addiction's grip might share a common pathway, one we're finally learning to interrupt.

The woman at the dinner party didn't develop superhuman willpower or become a different person—the signal driving her cravings simply went quiet.